Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

The ordinary s NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape ...

In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...

SIL-204 showed synergistic efficacy with 5-fluorouracil, irinotecan and gemcitabine in preclinical models of pancreatic cancer. ZSilexion plans Phase 2/3 trials for SIL-204 in 2026 and raised $5 ...

SLXN stock touches 52-week low at $0.27 amid market challenges ...

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shot up 46.5% during mid-day trading on Wednesday .The company traded as high as $1.29 and last traded at $1.03. 66,915,194 ...

In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...